USPTO serial 79397815
C CARSGEN THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 10, 2026
- Examiner
- CROWDER-SCHAEFER, ANDREW W
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with C CARSGEN THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Adam Bell
Adam Bell Bell IP Law58 West Portal Avenue #121San Francisco, CA 94127United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical purposes; biological tissue cultures for medical purposes; stem cells for medical purposes; liquid medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; injectable medicinal solutions in the nature of pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes in the nature of pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; vaccines; biological preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases for medical purposes; blood preparations, namely, blood for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CARSGEN THERAPEUTICS CO., LTD.
- Other trademarks owned by CARSGEN THERAPEUTICS CO., LTD.
- Other trademarks owned by CARSGEN THERAPEUTICS CO., LTD.
- Other trademarks in Class 005
- Similar marks named C CARSGEN THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 30, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 10, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 10, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 10, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 20, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 20, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 14, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 22, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 17, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 17, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 14, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 5, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 19, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 19, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 26, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 4, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 4, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 22, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 21, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 18, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 18, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 28, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 20, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |